StockData
Biogen Inc. logo

Biogen Inc.

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3058% above fair value
$249.59+2.46 (+1.00%)

Close on Nov 20, 2026Market cap $36.89BP/E 106.7Yield –

Biogen Share-Based Compensation Expense by Quarter

Share-Based Compensation Expense ($M)

Biogen Share-Based Compensation Expense: $81.5M in Q3 2026, up 8.2% from a year earlier.

Latest, Q3 2026
81.5
Period ended Sep 30, 2026
Change on a year earlier
+8.2%
75.3 in Q3 2025
History
67 quarters
Since Q3 2008
Sources
57
Documents cited below

Where the Q3 2026 figure comes from

Calculated from reported figures: quarter = year-to-date − previous year-to-date (cash flow statement)

Source: Biogen Form 10-Q (filed 2026-10-28) ↗

Reported in SEC Form 10-Q / Form 10-K (GAAP Consolidated Financial Statements).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedShare-Based Compensation Expense ($M)Year on yearSource
Q3 2026Sep 30, 202681.5+8.2%Biogen Form 10-Q (filed 2026-10-28) ↗
Q2 2026Jun 30, 202677.4+3.3%Biogen Form 10-Q (filed 2026-07-29) ↗
Q1 2026Mar 31, 202684+3.7%Biogen Form 10-Q (filed 2026-04-29) ↗
Q4 2025Dec 31, 202559.6-20.6%Biogen Form 10-K (filed 2026-02-06) ↗
Q3 2025Sep 30, 202575.3-200.4%Biogen Form 10-Q (filed 2025-10-30) ↗
Q2 2025Jun 30, 202574.9-202.7%Biogen Form 10-Q (filed 2025-07-31) ↗
Q1 2025Mar 31, 202581+11.3%Biogen Form 10-Q (filed 2025-05-01) ↗
Q4 2024Dec 31, 202475.1+36.8%Biogen Form 10-K (filed 2025-02-12) ↗
Q3 2024Sep 30, 2024-75+15.7%Biogen Form 10-Q (filed 2024-10-30) ↗
Q2 2024Jun 30, 2024-72.9-1.6%Biogen Form 10-Q (filed 2024-08-01) ↗
Q1 2024Mar 31, 202472.8-3.7%Biogen Form 10-Q (filed 2024-04-24) ↗
Q4 2023Dec 31, 202354.9-18.3%Biogen Form 10-K (filed 2024-02-14) ↗
Q3 2023Sep 30, 2023-64.8-1.4%Biogen Form 10-Q (filed 2023-11-08) ↗
Q2 2023Jun 30, 2023-74.1+27.8%Biogen Form 10-Q (filed 2023-07-25) ↗
Q1 2023Mar 31, 202375.6+11.8%Biogen Form 10-Q (filed 2023-04-25) ↗
Q4 2022Dec 31, 202267.2+14.3%Biogen Form 10-K (filed 2023-02-15) ↗

Cite this data

StockData. (2026). Biogen Share-Based Compensation Expense ($M), quarterly Q3 2008–Q3 2026 [Data set]. Compiled from Biogen SEC filings and investor materials. https://stockdatahq.com/stocks/biib/kpis/db-sbc

See every metric in the Biogen KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?